Supreme Court Questions Wider Medicine Margin Caps: What Happened on 12 October 2026

On 12 October 2026, the Supreme Court of India asked why trade margin caps on anti-cancer medicines could not be extended to other drugs. The Centre told the Court it had decided to cap trade margins on anti-cancer medicines at 30% of the Maximum Retail Price (MRP). It estimated annual savings of about ₹2,500 crore for patients. The Court asked the Centre to submit modalities for wider price-control measures by the next hearing, scheduled for 27 October 2026. As of 14 October 2026, that hearing has not yet taken place.

Key facts at a glance

What the Court questioned

Why not extend the cap?

The bench sought wider price-control measures. It asked why the approach used for anti-cancer medicines could not apply to other drugs as well.

Price gaps the Court cited

• A saline drip costing ₹11 against a sale price of ₹270.
• An India-made cardiac stent costing about ₹5,000 against hospital prices above ₹25,000.
• The gap between cost and selling price of the antibiotic Azithromycin. The source gives no figures for this one.

The Centre's argument and the Court's response

The Centre's representative argued that trade margins help supply medicines to remote areas. The Court stated that ensuring price-controlled medicines are available to patients is a government responsibility.

Background: how medicine prices are controlled in India

Drugs (Prices Control) Order, 2013 (DPCO)

The DPCO sets ceiling prices for scheduled formulations listed in its Schedule I. The Department of Pharmaceuticals administers it through the National Pharmaceutical Pricing Authority (NPPA), which fixes and revises prices under this framework.

For a scheduled formulation, the ceiling price starts from the simple average of the prices to retailers of brands and generic versions with at least 1% market share, based on moving annual turnover. A 16% margin is then added. The ceiling price becomes the MRP limit, and manufacturers may allow wholesaler and retailer margins within that limit.

Do not confuse the two figures. The 16% margin is part of the DPCO ceiling-price formula. The 30% figure is the trade-margin cap the Centre told the Court it had decided on for anti-cancer medicines. The source does not explain how the two relate.

National List of Essential Medicines (NLEM)

The Ministry of Health and Family Welfare prepares the NLEM with advice from the Standing National Committee on Medicines. Its review considers the World Health Organization's Essential Medicines List, national health programmes, the Indian Pharmacopoeia and the National Formulary. The 2022 NLEM, the list cited in the proceedings, has 388 drugs and more than 900 formulations. The source describes NLEM inclusion and DPCO price control as connected parts of the pricing framework.

Legal and institutional facts

• The Essential Commodities Act, 1955, is the legal basis for regulating the production, supply and distribution of essential commodities.
• The DPCO, 2013, is issued under that Act.
• The NPPA was established in 1997 as an attached office of the Department of Chemicals and Petrochemicals, according to the source.

What the source does not say

• It does not name the case or petition before the bench, or the legal question the Court is examining.
• It does not give the text of any order, or say whether the Court has directed any price cap beyond anti-cancer medicines.
• It does not say when the 30% cap on anti-cancer medicines takes effect, or which medicines it covers.

Treat the report as a summary of one hearing, not a final ruling. The 27 October 2026 hearing is the next step. No outcome from it can be reported until it happens.

Why this matters for exam revision

The topic links polity and governance (the Court's role in policy matters), the economy (price regulation) and health policy (essential medicines). Revise the full forms, the institutions and the figures above. This post makes no claim that any question on it will appear in an exam.

FAQ

Has the Supreme Court capped margins on all medicines?

The source does not say so. It reports that the Court questioned why the anti-cancer cap could not be extended and asked the Centre for modalities.

What is the next date to remember?

27 October 2026, the scheduled next hearing, which is still upcoming as of 14 October 2026.

Practice MCQs

Question 1

On what date did the Supreme Court question why trade margin caps on anti-cancer medicines could not be extended to other drugs?

1. 12 October 2026
2. 13 October 2026
3. 27 October 2026
4. 1 October 2026

Answer: 12 October 2026 — the source says the Court raised the question on that date; 13 October is the publication date and 27 October is the next hearing.

Question 2

At what percentage of MRP did the Centre tell the Court it had decided to cap trade margins on anti-cancer medicines?

1. 16%
2. 30%
3. 1%
4. 25%

Answer: 30% — the Centre said it capped trade margins on anti-cancer medicines at 30% of MRP, with estimated annual savings of about ₹2,500 crore.

Question 3

Which body administers the Drugs (Prices Control) Order, 2013 through the NPPA?

1. Ministry of Health and Family Welfare
2. Standing National Committee on Medicines
3. Department of Pharmaceuticals
4. World Health Organization

Answer: Department of Pharmaceuticals — the source says it administers the DPCO through the National Pharmaceutical Pricing Authority.

Question 4

How many drugs does the 2022 National List of Essential Medicines (NLEM) contain, according to the source?

1. 388
2. 900
3. 16
4. 2,500

Answer: 388 — the source says the 2022 NLEM contains 388 drugs and more than 900 formulations.

Question 5

What did the Supreme Court ask the Centre to submit by the next hearing on 27 October 2026?

1. A list of all essential medicines
2. Modalities for wider price-control measures
3. A report on the Essential Commodities Act, 1955
4. A new DPCO Schedule I

Answer: Modalities for wider price-control measures — the bench asked the Centre to submit these by the next hearing.